Viking Therapeutics closed its upsized offerings of 9,035,714 common shares at $35.00 each and $258.75M in 2.00% convertible notes due 2032. Underwriters fully exercised options on both tranches. Net proceeds of ~$547.8M will fund VK2735 and VK3019 programs.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
